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MicroRNA 141 is associated to 
outcome and aggressive tumor 
characteristics in prostate cancer
Elin Richardsen1,2, Sigve Andersen3,4, Christian Melbø-Jørgensen5, Mehrdad Rakaee1, 
Nora Ness1, Samer Al-Saad1,2, Yngve Nordby  3,6, Mona I. Pedersen3, Tom Dønnem3, 
Roy M. Bremnes3,4 & Lill-Tove Busund1,2
A large number of miRNAs influence key cellular processes involved in prostate tumorigenesis. 
Previous studies have demonstrated high expression of miRNAs in human prostate cancer (PC) tissues 
and cell lines. In previous microarray data, we found miR-141 to be upregulated and miR-145 to be 
downregulated in PC. In this large PC cohort (n = 535), we explored the prognostic role of miR-141 
and miR-145 in PC. Tumor epithelial (TE) and tumor stromal (TS) areas were evaluated separately 
and combined (TE + TS). In situ hybridization was used to evaluate the expression of the miRNAs. We 
found that miR-141 (TE) correlated significantly to Gleason score ≥8 (p = 0.040) and large tumor size 
(≥20 mm, p = 0.025) and miR-141 (TE + TS) to Gleason grade (p = 0.001). MiR-145 correlated to pT-
stage (p = 0.038), tumor size (p = 0.025), Gleason grade (p = 0.051) and PSA (p = 0.032). In univariate 
analysis miR-141 (TE + TS) was significantly associated with biochemical failure-free survival (BFFS, 
p = 0.007) and clinical failure-free survival (CFFS, p = 0.021). For miR-145, there were no differences 
between patients with high versus low expression. In multivariate analysis overexpression of miR-
141 in tumor epithelium and tumor stroma was significantly associated with BFFS (HR = 1.07 CI95% 
1.00–1.14, p = 0.007). To conclude, high expression of miR-141 appears associated with increased risk of 
biochemical PC recurrence.
Prostate cancer (PC) is one of the leading causes of death among men in developed countries, but disease out-
come is difficult to predict1. Over the last 30 years there has been a 25-fold increased number of radical prosta-
tectomies (RP), which is consistent with the observed incidence increase of PC. This increase is mainly related 
to overdiagnosis due to PSA testing2. Recent studies have indicated that PSA concentration is unable to differ-
entiate between indolent PC or life-threatening cancers at time of diagnosis3. Despite numerous of studies on 
prognostic- and predictive biomarkers, there is still an urgent need for more accurate stratification of aggressive 
versus indolent disease.
The involvement of miRNAs in gene regulatory processes and their implications in several solid cancers, 
including PC, make them attractive candidates for refining diagnosis, prognosis, and treatment options. miRNAs 
are a class of small noncoding RNA molecules that post-transcriptionally modulate gene expression by binding 
to the 3’- untranslated region (3′-UTR) of the target mRNA, and induce silencing of mRNA by the Argonaut 
(Ago) protein in the RNA-induced Silencing protein complex (RISC)4. Individual miRNAs are often deregulated 
in cancer since they are located in regions of the genome that are commonly overexpressed or deleted5. miRNAs 
are mediated by gene signaling such as deletions, amplifications, mutations, and epigenetic alterations of DNA. 
As a result, miRNAs can affect the synthesis of proteins necessary for tumorigenesis, disease progression, and 
metastasis4,5.
Today, there is a considerable data indicating that several miRNAs and their targets are abnormally expressed 
in PC6,7. This, alters a large range of cellular processes, including apoptosis-avoidance, cell proliferation, migration 
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and the androgen signaling pathways8,9. Circulating miR-141 is consistently up-regulated in PC compared with 
healthy controls10,11 and has been suggested as biomarker for biochemical failure and clinical outcome12,13. In 
treated and untreated LnCaP cells in vitro and in PC xenografts in intact and castrated mice, miR-141 had the 
greatest androgen-dependent expression14. Studies of prostate tumor epithelial and adjacent stromal cells have 
shown that miR-141 expression was restricted to the epithelium13. Despite numerous studies on biogenesis and 
mechanisms of miR-141 in PC pathogenesis10–14, the accurate expression and mechanistic function is largely 
unclear.
miR-145 is down-regulated in metastatic PC tissue15. miR-145 is assumed to play a beneficial role in 
epithelial-mesenchymal transition (EMT) by suppression of mesenchymal markers (fibronectin) and 
up-regulation of the epithelial marker E-cadherin6,16.
From our previous microarray screening study in a limited number of human PC tissues, we found 600 of 
1435 miRNAs to be highly expressed. Of these, the 50 miRNAs with the highest standard deviation (SD) were 
further analyzed, and the seven most up- or downregulated, which included miR-141 and miR-145, were vali-
dated by RT-qPCR17.
In the present study, we report the expression of mir-141 and miR-145 in TE cells and TS areas in human pros-
tatectomy specimens and their impact on biochemical failure free survival (BFFS), clinical failure-free survival 
(CFFS) and prostate cancer death (PCD).
Materials and Methods
Patient characteristics. All radical prostatectomy samples were collected from archives of the Departments 
of Pathology in two different health regions in Norway (1995–2005), Northern Norway and Central Norway 
regional authorities. 671 patients were included, of these were 136 excluded due to pelvic radiotherapy prior 
surgery, previous non-superficial cancer within 5 years of PC diagnosis, lack of follow-up data and inadequate 
paraffin-embedded tissue blocks. The final study cohort consisted of 535 patients with complete follow-up data. 
Median age at surgery was 62 (47–75) years, median PSA was 8.8 (range 0.7–104.0) ng/ml, and median tumor 
size was 20 (range 2.0–50) mm. At last follow-up (Dec 2016) 37% had experienced BF, 11% CF and 3.4% PCD. 
None of the patients received pre-operative hormonal therapy. Follow-up time was defined from the date of 
surgery until November 31, 2015, with time of biochemical failure (BF), clinical failure (CF) and prostate cancer 
death (PCD) as endpoints. BF was characterized as PSA ≥ 0.4 ng/ml rising in a minimum of two different blood 
samples postoperatively. BF-free survival (BFFS) was the time from surgery to PSA threshold. CF was defined as 
local symptomatic progression and/or metastasis to bone, visceral organs or lymph nodes on CT, MR, bone scan 
or ultrasonography. CF-free survival (CFFS) was the time from surgery to CF.
For more extensive information regarding patients, exclusion, definitions of variables and endpoints see our 
previous report18. The tumors were re-graded in 2018 according to the updated WHO guidelines19,20.
Tissue microarray construction. Tissue microarray (TMA) was used for the analyses. The cases were 
histologically reviewed by one uropathologist (ER) and the most representative areas of epithelial tumor cells 
and adjacent tumor stroma were selected for the donor block. The TMAs were made by using a tissue-arraying 
instrument (Beecher Instruments, Silver Springs, MD). The detailed methodology has been reported previously21. 
A 0.6 mm stylet was used to sample. Core samples from two different areas of neoplastic epithelial tumor cells and 
two of adjacent tumor stroma were collected. Prostate cores from 20 patients without any history of malignancy 
were used as negative controls. The core samples were inserted into an empty recipient paraffin block according 
to a predefined coordinate pattern.
In situ hybridization (ISH). Chromogen in situ hybridization (cISH) was performed both manual and auto-
matic. We used labelled locked nucleic acid (LNA) modified probes from Exiqon; miR-141 (hsa-miR-141–3p 
MIMAT0000432, miRCURY LNA Prod. No. 38042-15) and miR-145 (hsa-miR-145-5p MIMAT0000437, miR-
CURY LNA Prod. No. 88068-15). The Positive control (U6 hsa/mmu/rno, No 99002-15) consolidate good sensi-
tivity of the method with distinct and strong staining. As negative control, we used the scrambled-miRNA (No. 
99004-15). As positive and negative tissue control, we used a multi TMA-block, which included 12 different 
organs with normal and tumor tissue. RNAse-free water was used during sectioning and as diluent agent for 
buffer solutions. 4 µm TMA slides was attached to Super Frost Plus slides by overnight heating (60 °C).
MANUAL protocol: Sections were deparaffinized in xylene (3 × 10 min) and hydrated in ethanol solutions to 
PBS (pH 7.4). Proteinase-K 20 µg/ml treatment were done in PK-buffer (5 mM Tris-HCL, pH 7.5, 1 mM NaCl, 
autoclaved) at 37 °C for 20 min in a ThermoBrite hybridizer. After this treatment, TMAs were rehydrated through 
ethanol and air-dried. The LNA-probes were denatured by heating to 90 °C for 4 min.
Hybridization of the LNA-probes miR-141 (25 nM), scrambled miRNA (50 nM) and U6 (2 nM) was done 
by using a ThermoBrite hybridizer (50 °C for 60 min). Washes was done in room temperature by using 5 x SSC 
buffer, pre-heated SSC buffers (50 °C): 5 min in 5 x SSC, 2 × 5 min in 1 x SSC, 2 × 5 min in 0.2 SSC, and 5 min in 
RT 0.2 x SSC. The blocking solution was DIG wash (11 093 274 910, Roche, Mannheim, Germany) and Block 
buffer set (11 585 762 001, Roche, Mannheim, Germany) for 15 min in a humidity chamber. Alkaline phosphatase 
(AP)-conjugated anti DIG 1:800 was incubated for 30 min at 30 °C in a humidity chamber for immunologic detec-
tion. After PBS-T wash the substrate enzymatic reactions was carried out with NBT/BCIP (11 697 471 001, Roche, 
Mannheim, Germany) at 30 °C in the ThermoBrite for 120 min. To stop the reaction, we used KTBT buffer (50 nM 
Tris-Hcl, 150 nM NaCl, 10NM KCI) for 2 × 5 min, followed by wash in double distilled water.
Counterstaining of section was done by use of nuclear fast red (WALDECK, ZE-012-250) at room temperature 
before water tap rinse. The last step was the dehydration by ethanol at increasing gradients and mounting of the 
Histokitt mounting medium (Assistant-Histokitt, 1025/250 Sondheim/Rhoen Germany).
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AUTOMATIC protocol in Discovery Ultra: For miR145, sections were deparaffinized in EZ Prep (Roche 950-
100) at 68 °C (3 × 12 min). Pretreatment heating was done at 95 °C with CC1 (Roche 950-500), for hsa-miR-145 
(32 min), and scrambled miRNA (24 min). For U6, we used a combination of heat mediated and enzymatic pre-
treatment (CC1 for 8 min at 95 °C, Protease III, Roche 760-2020 for 16 min at 37 °C). After pretreatment, the 
sections were rinsed by using Reaction Buffer (Roche 750-300), followed by RiboWash, SSPE (Roche 760-105). 
The probes were diluted in 1:1 Exiqon microRNA ISH buffer (product No.9000) and Elix RNAse free water. 
MiR-145 (50 nM), scramble miRNA (10 nM) and U6 (0.5 nM) were applied and denaturation was 8 min at 90 °C. 
Hybridization in 60 min was done for Mir-145 (50 °C), scrambled MiRNA (57 °C) and U6 (55 °C). We washed 
with 2.0X RiboWash, SSPE buffer for 2 × 8 min and used the same temperatures as for the hybridization proce-
dure. After rinsing with Reaction Buffer, sections were blocked against unspecific binding for 12 min at 37 °C 
(from DIG wash and Block buffer set, 11 585 762 001, Roche, Mannheim, Germany).
For the immunologic detection, we used prediluted Alkaline phosphatase (AP)-conjugated anti DIG 
(Anti-DIG-AP, Roche 760-4825) for 20 min at 37 °C. The sections were rinsed with Reaction Buffer and EZ Prep 
before the substrate enzymatic reactions for 20 min at 37 °C (NBT/BCIP CromoMap Blue kit, Roche 760-161). 
The sections were rinsed once more with Reaction Buffer and counterstained for 4 min with Red Stain II (Roche 
780-2218). The last step was the dehydration process, which was done by using ethanol solutions and mounted 
with Histokitt mounting medium (Assistant-Histokitt, 1025/250 Sondheim/Rhoen Germany).
To ensure good distribution of reagents and to protect section from drying, all incubations were added LCS 
(Liquid Coverslip oil, Roche 650-010).
Data availability. The datasets generated during and or analyzed during the current study are available from 
the corresponding author on reasonable request.
Scoring of in situ hybridization. We used the ARIOL imaging system (Genetix, San Jose, USA) in the 
scoring process of the TMAs. The TMAs were scanned at low resolution (1.25x) and high resolution (20x) by 
using Olympus BX 61 microscope. We scored, semi-quantitatively, TE and TS separately. Both intensity and 
density were scored. Intensity scoring scale: 0 = negative, 1 = weak, 2 = moderate, 3 = strong. Density was scored 
as follows: percentage positive cells examined in TE or TS was scored by using the following system: 0 = 0%, 
1 = ≤5%, 2 = 5–50%, 3 ≥50%, then a mean score was calculated. The scoring values were dichotomized into 
high or low intensity. In both TE and TS areas, the cut-off was defined as the density level × 4th quartile. High 
co-expression (TE + TS) of miR-141 and miR-145 was defined as low expression (≤1) and high expression (≥2). 
The samples were anonymized and independently scored (ER/CMJ and ER/SAS). In case of disagreement, the 
slides were re-examined until a final consensus was reached.
Statistical methods. The IBM SPSS, version 24 (SPSS Inc., Chicago, IL, USA) was used for statistical analy-
ses. Wilcoxon signed rank test was used to assess differences in miR-141 and miR-145 expression between normal 
tissue and cancer tissue. Spearman’s Correlation coefficient was used for correlation analysis between miR-141 
and miR-145 expression and clinicopathological markers. The Kaplan-Meyer method was used for drawing sur-
vival plots for BF and CF, and statistical differences was done by using log-rank test. Variables from the univariate 
analyses with a p < 0.05 were included in a multivariate survival analysis by using a backward stepwise multi-
variate Cox regression model with a probability for stepwise entry removal at 0.05 and 0.10, respectively. The 
significance level was set to p-value <0.05.
Ethics. The current study was approved by the Regional Committee for Medical and Health Research Ethics, 
REK Nord (Project Application 2009/1393), including a mandatory re-application January 22. 2016. Due to the 
retrospective study design, the tissue blocks were collected from 1995 and 2005, and many patients were deceased, 
REK Nord considered written consent not to be necessary. In addition, the Data Protection Official for Research 
and The National Data Inspection Board approved the establishment of the database. The patient records were 
anonymized prior to the analyses. The reporting of clinicopathological variables, survival data and biomarker 
expressions was conducted in accordance with the REMARK guidelines.
Results
Patient characteristics. Patients’ characteristics are presented in Table 1. Median age at surgery was 62 
(47–75) years, median PSA was 8.8 (range 0.7–104.0) ng/ml, and median tumor size was 20 mm (range 2.0–50). 
The prostatectomies specimens were retropubic in 435 and perineal in 100 cases. At the end of follow-up, 200 
(37%) patients had BF, 56 (11%) had CF, and 18 (3%) were dead of PC.
Expression of miR-141 and miR- 145 and their correlations to clinicopathological variables. Of 
the total cohort, for miR-145 we had 495 cores available for miR-145 scoring, 248 with low expression and 247 
with high expression. miR-145 was weaker in normal epithelial- and stromal cells compared to cancer tissue. Its 
staining pattern was nuclear and mainly in TE (Fig. 1A,C,E). For miR-141 we had 463 cores available for scoring, 
164 cores with low expression and 299 cores with high expression. Overall, the expression of miR-141 was higher 
in tumor tissue compared with normal prostatic tissue, and mainly in TE (Fig. 1B,D,F). The correlation between 
the miRs expression and clinicopathological variables were weak or non-significant (r = <0.2). MiR-141 in TE 
correlated significantly to Gleason score (p = 0.040) and large tumor size (p = 0.050), and in TE + TS to Gleason 
score (p = 0.001). MiR 145 (TE + TS) correlated to pT-stage (p = 0.038), tumor size (p = 0.025), Gleason score 
(p = 0.051) and pre-operative PSA (p = 0.032).
Univariate analyses. PC patients with high co-expression (TE + TS) of miR-141 had significantly lower 
BFFS, Fig. 2A (p = 0.007) and CFFS, Fig. 2B (p = 0.021) than patients with low expression. Analyzing mir-
141 separately in TE and TS, only TE was significant for BFFS (p = 0.045), but not for CFFS (p = 0.746). The 
www.nature.com/scientificreports/
4SCIENTIfIC REPORts |           (2019) 9:386  | DOI:10.1038/s41598-018-36854-7
clinicopathological variables which were associated with BFFS, CFFS and PCDFS are listed in Tables 1 and 2. 
Shortly, the following was associated with BFFS; pT-stage, preoperative PSA, Gleason grade, tumor size, perineu-
ral infiltration (PNI), positive surgical margin (PSM), non-apical PSM and vascular infiltration (VI). Association 
with CFFS; pT-stage, Gleason grade, tumor size, PNI, PSM, and VI. For PCD; pT-stage, preoperative PSA, 
















Age NS 0.008 NS
≤65 years 357 (67) 76 92 97
>65 years 178 (33) 70 88 96
pT-stage <0.001 <0.001 <0.001
pT2 374 (70) 83 96 98
pT3a 114 (21) 60 86 98
pT3b 47 (9) 43 73 89
Preoperative PSA <0.001 NS <0.001
PSA < 10 308 (57) 81 93 99
PSA > 10 221 (42) 68 88 95
Missing 6 (1)
Gleason Grade Group <0.001 <0.001 <0.001
1 (3 + 3) 183 (34) 83 98 99
2 (3 + 4) 220 (41) 77 93 98
3 (4 + 3) 8 (15) 70 84 95
4 (4 + 4) 19 (4) 59 76 94
5 (≥9) 33 (6) 37 67 87
Tumor Size <0.001 0.019 NS
0–20 mm 250 (47) 83 94 99
>20 mm 285 (53) 68 88 96
PNI <0.001 <0.001 0.002
No 401 (75) 83 95 98
Yes 134 (25) 68 81 93
PSM 0.049 NS NS
No 249 (47) 81 94 97
Yes 286 (53) 69 89 97
Non-apical PSM <0.001 <0.001 0.022
No 381 (71) 82 95 98
Yes 154 (29) 57 81 94
Apical PSM NS NS NS
No 325 (61) 74 90 96
Yes 210 (39) 77 92 98
Vascular infiltration <0.001 <0.001 <0.001
No 492 (92) 77 93 98
Yes 43 (8) 47 71 88
Surgical procedure NS NS NS
Retropubic 435 (81) 77 90 97
Perineal 100 (19) 68 95 98
miR-141 (TE + TS) 0.007 0.021 NS
High 299 126 38 11
Low 164 50 10 5
miR-145 (TE + TS) NS NS NS
High 247 91 27 10
Low 248 97 25 7
Table 1. Summary of patient characteristics, clinicopathological variables, miR-141 and miR-145. Univariate 
analyses; log-rank test. Abbreviations: BF = biochemical failure; EFS = event free survival, CF = clinical failure. 
PCD = prostate cancer death; P = p-value; PNI = perineural infiltration; PSM = positive surgical margin; 
NS = not significant.
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For miR-145, there were no association with BFFS (p = 0.348), CFFS (p = 0.895) or PCDFS (p = 0.520) when 
assessed in patients with high versus low expression. When analyzing TE and TS as separate compartments, or 
combined (TE + TS) no association were found for miR-145.
Multivariate analyses. In the multivariate analyses (Table 2), high expression of miR-141 (TE + TS) was 
borderline significant for BFFS (HR = 1.07 95% CI 1.00–1.14, p = 0.050), not with CFFS (HR = 2.32 95% CI 
0.94–5.73, p = 0.068). In addition, the following clinicopathological variables were significant predictors for 
Figure 1. Immunohistochemical staining of (A) miR-145 and (B) miR-141. High expression of mir-145 (A) 
and miR-141 (B). Low expression of miR-145 (C) and miR-141 (D). Normal prostate tissue, miR-145 (E) and 
miR-141. Scrambled miR-145 (G), miR-141 (H) and U6, miR-145 (I) and miR-141 (J).
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BFFS: pT-stage (p < 0.001), Gleason score (p = 0.036), PSM (p = 0.002), non-apical PSM (p = 0.003), apical PSM 
(p = 0.033) and PNI (p = 0.011). CFFS, age (p = 0.024), Gleason grade group (p = 0.005), and for PCDFS, only VI 
(p = 0.002) and PNI (HR = 0.17, 95% CI 0.06–0.50, p = 0.001).
Discussion
In this large cohort of 535 radical prostatectomy specimens we found that the expression of miR-141 was associ-
ated with an increased risk of BFFS and CFFS from PC. Both by analyzing the tumor tissue as one compartment 
(TE + TS) or only in the TE compartment we found the same association for increased risk of biochemical- and 
clinical failure. Nevertheless, which role the various miRNAs play at different stages of PC progression and how 
their expression change during the multistep carcinogenesis, is poorly understood.
We found that miR-141 was mainly expressed in the TE, which is consistent with cell line studies12,14. Most 
studies on miR-141 are, however, from liquid biopsies such as urine, serum, plasma and whole blood. Mitchell 
et al.22. reported that tumor-derived miRNAs can enter the circulatory system and be measured in serum and 
plasma as important blood-based biomarkers of human cancer. The authors showed that circulating miR-141 is 
significantly elevated in the sera of PC patients compared to healthy controls22. Brase et al.12. reported that high 
levels of circulating miR-141 were associated with more aggressive and advanced disease (high Gleason score and 
lymph node metastases), Waltering et al. showed that miR-141 up-regulation in plasma of metastatic PC patients 
as well as in cell lines after castration, and that this up-regulation induced growth of LNCaP cells14. This may 
Figure 2. miR-141 (TE + TS). Patients cohort were dichotomised into low and high-risk groups evaluated by 
using Kaplan-Meier analysis of, (A) Biochemical failure-free survival. (B) Clinical failure-free survival. The 
p-value for a two-sided log rank test is shown for both.
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imply that miR-141 regulate androgen, which plays a crucial role in the growth of both androgen-dependent and 
castration-resistant PC. Besides, Agaoglu et al.11. reported a significantly higher circulating miR-141 in patients 
with locally advanced-stage disease. Measured in liquids (blood and serum), miR-141 seems to be one of the more 
promising markers for PC progression11–13.
There is mounting evidence that the androgen receptor (AR) is not the only effective endocrine receptor in 
this complex process14. Previous studies suggest involvement of both the glucocorticoid-, estrogen- and proges-
terone receptors23–25. One study by Larne et al. found that miR-145, by suppressing the AR in PC cells, correlated 
to PC prognosis26. Their results were verified in clinical prostate specimens by demonstrating inverse correlations 
between miR-145 and AR expression as well as serum PSA levels. In addition, miR-145 was found to regulate 
androgen-dependent cell growth in vitro. IHC studies on PR expression in PC have demonstrated contradicting 
results and only a few reports have addressed the roles PR’s plays in prostate carcinogenesis. We have previously 
demonstrated a general distribution of PR in tumor epithelium of PC27. The present findings of a correlation 
between miR-141 expression in PC tumor tissue and PR suggest that mRNAs may also be involved in PR regula-
tion or vice versa.
We found that miR-145 was weakly expressed in both tumor tissue and normal prostatic tissue and was corre-
lated to clinicopathological variables associated with worse outcome. In spite of this, miR-145 was not associated 
with biochemical- or clinical failure. Our findings are in line with Pang et al. and Schaefer et al. failing to detect 
any associations between miR-145 and clinicopathological variables6,28. However, other studies have reported 
that loss of the tumor suppressing properties of miR-145 is correlated with a higher Gleason grade, bone metas-
tases and shorter disease-free survival29,30. Downregulation of miR-145 may lead to enhanced cell proliferation, 
migration, and invasion in PC29. Fuse et al. also demonstrated that the capacity of PC3 and DU145 PC cells lines 
to proliferate, migrate, and invade was impaired by transfection with miR-14531. miR-145 may inhibit PC cell 
proliferation by targeting Fasin homolog 1 (FSCN1), an actin bundling protein, which is involved in cell motility, 
adhesion and cellular interactions during tumorigenesis and metastasis31.
Some of the innate properties of miRNAs make them attractive as potential biomarkers, as they may can 
be isolated from most body fluids and easily detected in small volume samples. However, their profile is not 
organ-specific and discrimination between different types of malignancies is not yet possible32,33. An ideal bio-
marker of tumors, measured in liquid biopsies or in FFPE, should be specific, sensitive, and proportional to tumor 
load. Studies have demonstrated that for many of the miRNAs, the circulating miRNAs and tissue miRNAs are 
Characteristics
BFFS CFFS






pT3a 0.31 0.21–0.56 <0.001
pT3b 0.57 0.36–0.90 0.017
Gleason Grade Group 0.036 0.005
1 (3 + 3) 1 1
2 (3 + 4) 0.54 0.30–0.98 0.043 0.10 0.03–0.34 <0.000
3 (4 + 3) 0.72 0.41–1.26 0.250 0.42 0.19–1.00 0.039
4 (4 + 4) 1.02 0.57–1.84 0.947 0.56 0.23–1.35 0.195









Yes 0.65 0.47–0.91 0.17 0.06–0.50
miR-141 (TE + TS) 0.050 NS
Low 1
High 1.07 1.00–1.14
Table 2. High expression of miR-141 is a prognostic factor in prostate cancer of 535 patients. Multivariate 
analyses; Cox regression with backward conditional. Abbreviations: BFFS = biochemical failure-free survival, 
CFFS = clinical failure-free survival. PSM = positive surgical margins; PNI = perineural infiltration; TE = tumor 
epithelium; TS = tumor stroma areas.
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comparable. High tumoral association of miRNAs in liquid biopsies is not necessarily equal to the level expressed 
at protein level when measured by tumor tissue immunohistochemistry. Moreover, FFPE is an extremely power-
ful preservation agent. Therefore, once a tissue specimen is fixed, it can be stored at room temperature for years, 
unlike current preservation properties of miR’s.
Possible limitation of our study includes its retrospective nature as well as the use of old tissue blocks, which 
could have affected the results of hematoxylin/eosin and immunohistochemical staining. However, fresh sections 
were cut and stained for best results. To the best of our knowledge this is the largest study visualizing miR-141 and 
mir-145 on hormone naïve PC tissue by using IHC.
Conclusions
We found that high expression of miR-141 to be significantly associated to worse PC outcome. In TE a high 
expression was associated with BFFS and in TE + TS was associated with a higher risk of BFFS and CFFS. We also 
found that miR-145 correlated with more aggressive features of prostate cancer. This knowledge may be valuable 
for further studies, which should provide further mechanistical explanation for the role of miR-145 in PC, in 
particular regarding target genes of the miR in PC.
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